These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17390117)

  • 1. [Endogenous anticoagulant therapy for sepsis. Success and failure].
    Wiedermann CJ
    Internist (Berl); 2007 May; 48(5):537-42, 544. PubMed ID: 17390117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PROWESS--milestone in lowering sepsis mortality].
    Reinhart K
    Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
    [No Abstract]   [Full Text] [Related]  

  • 3. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
    McCoy C; Matthews SJ
    Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
    Maki DG
    Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
    [No Abstract]   [Full Text] [Related]  

  • 5. Drotrecogin Alfa (Activated): From Bench to Practical Use at the Bedside. Proceedings of meetings of the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Clinical Evaluation Committee.
    Am J Surg; 2002 Dec; 184(6A Suppl):1S-49S. PubMed ID: 12521610
    [No Abstract]   [Full Text] [Related]  

  • 6. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
    Sollet JP; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis].
    Spies C; Otter H; Zuckermann-Becker H; Kox WJ
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
    Morris PE; Light RB; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S19-24. PubMed ID: 12521614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging therapies for sepsis.
    Healy DP
    Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.
    Dhainaut JF
    Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612
    [No Abstract]   [Full Text] [Related]  

  • 14. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy].
    Haas I
    Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015
    [No Abstract]   [Full Text] [Related]  

  • 15. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
    Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.
    Bachli EB; Vavricka SR; Walter RB; Leschinger MI; Maggiorini M
    Intensive Care Med; 2003 Feb; 29(2):337. PubMed ID: 12594601
    [No Abstract]   [Full Text] [Related]  

  • 17. Drotrecogin alfa (activated) for severe sepsis.
    Maglio D
    Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766
    [No Abstract]   [Full Text] [Related]  

  • 18. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.
    Lai PS; Matteau A; Iddriss A; Hawes JC; Ranieri V; Thompson BT
    Minerva Anestesiol; 2013 Jan; 79(1):33-43. PubMed ID: 23174922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe sepsis.
    Bernard G
    Am J Surg; 2002 Dec; 184(6A Suppl):S3-4. PubMed ID: 12521611
    [No Abstract]   [Full Text] [Related]  

  • 20. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
    Rice TW; Bernard GR
    Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.